A Phase 1 interventional study of 14C-IMP4297 in Solid Tumor, sponsored by Impact Therapeutics, Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Impact Therapeutics, Inc. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 Following a Single Oral Dose to China Healthy Male Subjects
Study design A Phase I, single-center, open-label, single arm study is designed to evaluate Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 Following a Single Oral Dose to China Healthy Male Subjects.
6-8 subjects are planned to be enrolled (at least 6 subjects complete the study)
Impact Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Volunteers must meet all of the following inclusion criteria to be included in the study:
Exclusion Criteria:
Volunteers who meet any of the following criteria cannot be included in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this study, one 100 mg dose of 14C IMP4297 Oral Suspension, 100 mg (100 μCi).
Drug: 14C-IMP4297
14C marked IMP4297
Cmax (Maximum concentration)
peak concentration
Time frame: 3 months
Tmax
Time to peak
Time frame: 3 months
AUC0-inf (Area under the curve from time 0 to infinity)
area under the curve from time zero to infinity
Time frame: 3 months
AUC0-last (Area under the curve from time 0 to the last time with quantifiable concentration)
AUC0-last area under the curve from time zero to the time with the last quantifiable concentration
Time frame: 3 months
t½ (Elimination half-life)
elimination half-life
Time frame: 3 months
CL/F (Apparent clearance)
apparent clearance
Time frame: 3 months
Vz/F (apparent volume of distribution )
apparent volume of distribution
Time frame: 3 months
urine and fecal samples for quantification analysis
Assessment of recovery percent in urine and feces by liquid chromatography-radiochemical-detection。 Get Percent (%) of each radiolabeled drug-related material will be determined in urine and feces
Time frame: 3 months
After oral administration of [14C] IMP4297 in healthy volunteers, radioactive metabolite spectrogram are obtained to identify the main metabolites and clarify the main biotransformation pathways.
Proportion of different metabolites,Assessment of metabolites (metabolites identification and main metabolites) in plasma/urine/faeces by liquid chromatography-radiochemical-detection
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in Dec 2021, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Impact Therapeutics, Inc.